medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2014, Número 3

<< Anterior Siguiente >>

Arch Neurocien 2014; 19 (3)


Efecto de la simvastatina en vasoespasmo e isquemia cerebral retardada en pacientes con hemorragia subaracnoidea aneurismática

Juárez-Reyes S, Arauz-Góngora A

Idioma: Español
Referencias bibliográficas: 55
Paginas: 121-128
Archivo PDF: 147.45 Kb.


RESUMEN

La enfermedad vascular cerebral (EVC) constituye la segunda causa global de muerte (97 %) de las cuales el 89% sucede en países de ingresos bajos o medios. La hemorragia subaracnoidea aneurismática (HSA) es un subtipo de EVC, que afecta cualquier edad; corresponde al 5% de eventos cerebrovasculares situándola en la cuarta causa de estos. El presente trabajo es un ensayo clínico aleatorizado, doble ciego, controlado con placebo que se lleva a cabo en el Instituto Nacional de Neurología y Neurocirugía de junio 2013 a febrero 2014, se incluyeron a 20 pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Feigin VL, Krishnamur thi R. Public health strategies could reduce the global stroke epidemic. Lancet Neurol 2010;9(9): 847-8.

  2. Lavados PM, Hennis AJ, Fernandes JG, Medina MT, Legetic B, Hoppe A, et al. Stroke epidemiology prevention, and management strategies at a regional level: Latin America and the Caribbean. Lancet Neurol 2007;6(4):362-72.

  3. Bederson JB, Connolly ES, Jr, Batjer HH, Dacey RG, Dion JE, Diringer MN, et al. Guidelines for the management of aneur ysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Hear t Association. Stroke J Cereb Circul 2009;40(3):994-1025.

  4. Linn FH, Rinkel GJ, Algra A, van Gijn J. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography: a meta-analysis. Stroke J Cereb Circul 1996;27(4):625-9.

  5. Epidemiology of aneur ysmal subarachnoid hemorrhage in Australia and New Zealand: incidence and case fatality from the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). Stroke J Cereb Circul 2000; 31(8):1843-50.

  6. Feigin VL, Anderson CS, Rodgers A, Bennett DA. Subarachnoid haemorrhage occurrence exhibits a temporal pattern - evidence from meta- analysis. Eur J Neurol Off J Eur Fed Neurol Societies 2002;9(5):511-6.

  7. Van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain J Neurol 2001;124(Pt 2):249-78.

  8. Topcuoglu MA, Ogilvy CS, Carter BS, Buonanno FS, Koroshetz WJ, Singhal AB. Subarachnoid hemorrhage without evident cause on initial angiography studies: diagnostic yield of subsequent angiography and other neuroimaging tests. J Neurosurg 2003;98(6):1235-40.

  9. Hentschel S, Toyota B. Intracranial malignant glioma presenting as subarachnoid hemorrhage. The Canadian journal of neurological sciences Le Journal Canadien des Sciences Neurologiques 2003;30(1):63-6.

  10. Leng LZ, Fink ME, Iadecola C. Spreading depolarization: a possible new culprit in the delayed cerebral ischemia of subarachnoid hemorrhage. Arch Neurol 2011;68(1):31-6.

  11. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneur ysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta- analysis. Lan Neurol 2009;8(7):635-42.

  12. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB. Microthrombosis after aneur ysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. Journal of cerebral blood flow and metabolism: Off J Internat Soc Cereb Blood Flow Metab 2008;28(11): 1761-70.

  13. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneur ysmal subarachnoid hemorrhage: a guideline for healthcare professionals fr om the American Hear t Association/American Stroke Association. Stroke J Cereb Circul 2012;43(6):1711-37.

  14. Hijdra A, Van Gijn J, Stefanko S, Van Dongen KJ, Vermeulen M, Van Crevel H. Delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: clinic anatomic correlations. Neurol 1986;36(3):329-33.

  15. Kassell NF, Torner JC, Haley EC, Jr., Jane JA, Adams HP, Kongable GL. The International Cooperative Study on the Timing of Aneur ysm Surgery. Par t 1: Overall management results. J Neurosur 1990;73(1):18-36.

  16. Iadecola C. Bleeding in the brain: Killer waves of depolarization in subarachnoid bleed. Nat Med 2009;15(10): 1131-2.

  17. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Prac Neurol 2007;3(5):256-63.

  18. Igarashi T, Moro N, Katayama Y, Mori T, Kojima J, Kawamata T. Prediction of symptomatic cerebral vasospasm in patients with aneur ysmal subarachnoid hemorrhage: relationship to cerebral salt wasting syndrome. Neurol Resear 2007;29(8): 835-41.

  19. Hans P. Pharmacological therapeutic prospects of cerebral vasospasm. Annales Francaises D’anesthesie et de Reanimation 1996;15(3):374-81.

  20. Vermeulen M, van Gijn J. The diagnosis of subarachnoid haemorrhage. J Neurol Neurosur Psychi 1990;53(5):365-72.

  21. Kopitnik TA, Samson DS. Management of subarachnoid haemorrhage. J Neurol Neurosur Psych 1993;56(9):947-59.

  22. Manno EM. Subarachnoid hemorrhage. Neurol Clin 2004;22 (2):347-66.

  23. Beetham R. Recommendations for CSF analysis in subarachnoid haemorrhage. J Neurol Neuros Psych 2004; 75(4):528.

  24. Mitchell P, Wilkinson ID. Detection of subarachnoid haemorrhage with magnetic resonance imaging. J Neurol Neuros Psych 2001;70(2):205-11.

  25. Rabinstein AA, Lanzino G, Wijdicks EF. Multidisciplinar y management and emerging therapeutic strategies in aneur ysmal subarachnoid haemorrhage. Lancet Neurol 2010;9(5):504-19.

  26. Arimura H, Li Q, Korogi Y, Hirai T, Katsuragawa S, Yamashita Y, et al. Computerized detection of intracranial aneur ysms for three-dimensional MR angiography: feature extraction of small protrusions based on a shape-based difference image technique. Medical Physics 2006;33(2):394-401.

  27. Lysakowski C, Walder B, Costanza MC, Tramer MR. Transcranial Doppler vs angiography in patients with vasospasm due to a ruptured cerebral aneurysm: a systematic review. Stroke. J Cereb Circul 2001;32(10):2292-8.

  28. Sloan MA, Haley EC, Jr Kassell NF, Henry ML, Stewart SR, Beskin RR, et al. Sensitivity and specificity of transcranial Doppler ultrasonography in the diagnosis of vasospasm following subarachnoid hemorrhage. Neurol 1989; 39(11): 1514-8.

  29. Rosen DS, Macdonald RL. Subarachnoid hemorrhage grading scales: a systematic review. Neurocritical Care 2005; 2(2):110-8.

  30. Clarke G, Mendelow AD, Mitchell P. Predicting the risk of rupture of intracranial aneur ysms based on anatomical location. Act Neurochir 2005; 147 (3): 259-63; discussion 63.

  31. Horiuchi T, Tanaka Y, Hongo K. Surgical treatment for aneur ysmal subarachnoid hemorrhage in the 8th and 9th decades of life. Neurosur 2005;56(3):469-75;discussion-75.

  32. Origitano TC, Wascher TM, Reichman OH, Anderson DE. Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution («triple-H» therapy) after subarachnoid hemorrhage. Neurosur 1990;27(5): 729- 39; discussion 39-40. Epub 1990/11/01.

  33. Tseng MY, Al-Rawi PG, Pickard JD, Rasulo FA, Kirkpatrick PJ. Effect of hypertonic saline on cerebral blood flow in poorgrade patients with subarachnoid hemorrhage. Stroke; J Cereb Circul 2003;34(6):1389-96.

  34. van den Bergh WM, Algra A, van Kooten F, Dir ven CM, van Gijn J, Vermeulen M, et al. Magnesium sulfate in aneur ysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke; a J Cereb Circul 2005;36(5):1011-5.

  35. Shaw MD, Vermeulen M. Ef ficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemor rhage: a repor t by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosur 2000; 93(6):992-7.

  36. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. Clazosentan (AXV- 034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneur ysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebocontrolled, multicenter phase IIa study. J Neurosur 2005; 103(1):9-17.

  37. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007(3):CD000277.

  38. Sen J, Belli A, Albon H, Morgan L, Petzold A, Kitchen N. Triple- H therapy in the management of aneurysmal subarachnoid haemorrhage. Lancet Neurol 2003;2(10):614-21.

  39. Mutoh T, Kazumata K, Ishikawa T, Terasaka S. Performance of bedside transpulmonar y thermodilution monitoring for goal-directed hemodynamic management after subarachnoid hemorrhage. Stroke; a J Cereb Circul 2009;40(7):2368-74.

  40. Ekelund A, Reinstrup P, Ryding E, Andersson AM, Molund T, Kristiansson KA, et al. Ef fects of iso- and hyper volemic hemodilution on regional cerebral blood flow and oxygen deliver y for patients with vasospasm after aneur ysmal subarachnoid hemorrhage. Act Neurochirur 2002;144(7): 703-12; discussion 12-3.

  41. Raabe A, Beck J, Keller M, Vatter H, Zimmermann M, Seifert V. Relative impor tance of hyper tension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. J Neurosurgery 2005;103(6):974-81.

  42. Polin RS, Coenen VA, Hansen CA, Shin P, Baskaya MK, Nanda A, et al. Ef ficacy of transluminal angioplasty for the management of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurgery 2000; 92(2):284-90.

  43. Morgan MK, Jonker B, Finfer S, Harrington T, Dorsch NW. Aggressive management of aneur ysmal subarachnoid haemorrhage based on a papaverine angioplasty protocol. Journal of Clinical Neuroscience: Official J Neurosurg Society of Australasia 2000;7(4):305-8.

  44. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, et al. Intravenous magnesium sulphate for aneur ysmal subarachnoid hemorrhage (IMASH): a randomized, doubleblinded, placebo- controlled, multicenter phase III trial. Stroke; a J Cereb Circul 2010;41(5):921-6.

  45. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke; a J Cereb Circul 2008;39(11):3015-21.

  46. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneur ysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS- 2). Lancet Neurol 2011;10(7):618-25.

  47. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Preventing vasospasm improves outcome after aneur ysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocritical Care 2010;13(3):416-24.

  48. McGir t MJ, Lynch JR, Parra A, Sheng H, Pearlstein RD, Laskowitz DT, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke; J Cereb Circul 2002;33(12):2950-6.

  49. Lynch JR, Wang H, McGirt MJ, Floyd J, Friedman AH, Coon AL, et al. Simvastatin reduces vasospasm after aneur ysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke; a J Cereb Circul 2005;36(9):2024-6.

  50. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneur ysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke; a J Cereb Circul 2005;36(8):1627-32.

  51. Rabinstein AA. Vasospasm and statin therapy: yet another cautionar y tale. Neurocritical Care 2010;12(2):310-2.

  52. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke; a J Cereb Circul 1999;30(9):1969-73. Epub 1999/09/02.

  53. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343(6257):425-30.

  54. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutar yl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proceedings of the National Academy of Sciences of the United States of America 1998;95(15):8880-5.

  55. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke; a J Cereb Circ 2002;33(9):2337-41.




2020     |     www.medigraphic.com